Going Virtual at Cornell’s eLab
February 21, 2017
Entrepreneurship at Cornell (eLab) is a diverse, university-wide program that finds and fosters the entrepreneurial spirit in participants from every college, every field, and in every stage of life. Grounded in the belief that individuals who exhibit an entrepreneurial spirit and have acquired entrepreneurial knowledge can add significant value to any working environment from the smallest startup to the largest business, from non-profits to government agencies.
API-based genomics databank facilitates personalized medicine
December 1, 2016
Genomic testing is becoming an increasingly common starting place for the development of personalized medicine treatments for patients with a variety of hard-to-treat diseases, especially cancer, but organizations often struggle with interpreting and analyzing a glut of raw data produced by sequencing initiatives.
Tracing Cancer’s Roots
November 22, 2016
In a light-filled office, two young physician-scientists study how cancer forms, spreads, and recurs after remission. They meet once or twice a week where—amid leftover take-out containers and white-boarded walls—they write code, work through complex problems, and share recent triumphs and challenges.
EXaCT-1 Precision Medicine Cancer Test Validated for Clinical Usage
October 3, 2016
A powerful next-generation genome-sequencing test developed at Weill Cornell Medicine can detect mutations that guide precision cancer treatment with over 95 percent accuracy, according to new research.
Weill Cornell, New York Genome Center Win NCI Grant to Support New TCGA Phase
September 28, 2016
Investigators involved in the WCM-NYGC Weill Cornell Medicine-New York Genome Center (WCM-NYGC) for Functional and Clinical Interpretation of Tumor Profiles collaboration recently received just shy of $490,000 from the National Cancer Institute to help further data analysis for the Cancer Genome Atlas project.
New Big Data Approach Predicts Drug Toxicity in Humans
September 21, 2016
Researchers can now predict the odds of experimental drugs succeeding in clinical trials, thanks to a new data-driven approach developed by Weill Cornell Medicine scientists. The method detects toxic side effects that may disqualify drugs from human use, giving drug developers an early warning before initiating clinical trials, according to a new study published Sept. 15 inCell Chemical Biology.
Virtual Vision
September 10, 2016
In the 1966 film Fantastic Voyage, physicians were shrunk down to microscopic size to travel inside the human body and save a dying patient. Now, researchers at Weill Cornell Medicine are using virtual reality goggles to bring that fantasy to life—with the aim of improving cancer care.
Why we need precision medicine—now
September 1, 2016
The launch of President Obama’s Precision Medicine Initiative is putting a cutting-edge approach to research and patient care on the map. Academic medical centers have been pioneering the development of precision medicine for more than a decade—and now it’s time for the biopharmaceutical industry to get deeper in the game.
From ‘tache to test: Movember Foundation funds research into non-invasive blood test for metastatic prostate cancer
August 2, 2016
In order to benefit from the latest advances in precision medicine, Himisha Beltran, M.D., has to subject her prostate cancer patients to invasive biopsies that can be painful, expensive, difficult to perform, and not always feasible.
But she is hoping to harness new genomic sequencing technologies to track tumor activity from a simple blood draw, and a $1 million grant from the Prostate Cancer Foundation may help make the dream a clinical reality.
EXaCT-1 Precision Medicine Cancer Test Validated for Clinical Usage
July 19, 2016
A powerful next-generation genome-sequencing test developed at Weill Cornell Medicine can detect mutations that guide precision cancer treatment with over 95 percent accuracy, according to new research. The scientists say their findings, published July 20 in NPJ Genomic Medicine, validate the test, called Weill Cornell Medicine EXaCT-1, and demonstrate its feasibility in a clinical setting.